EDITORIAL

This publication has 15 references indexed in Scilit:

• Parathyroid 99m Tc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout
  European Journal of Nuclear Medicine and Molecular Imaging, 2002
• Worldwide Trends in the Surgical Treatment of Primary Hyperparathyroidism in the Era of Minimally Invasive Parathyroidectomy
  Archives of Surgery, 2002
• Presurgical Localization of Abnormal Parathyroid Glands Using a Single Injection of Tc-99m Sestamibi
  Clinical Nuclear Medicine, 2002
• ^99mTc-MIBI Radio-Guided Minimally Invasive Parathyroidectomy: Experience with Patients with Normal Thyroids and Nodular Goiters
  Thyroid®, 2002
• Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection.
  Endocrine-Related Cancer, 2001
• Technetium 99m-MIBI-SPECT: A highly sensitive diagnostic tool for localization of parathyroid adenomas
  Surgery, 2000
• Cost-Effectiveness of Preoperative Sestamibi Scan for Primary Hyperparathyroidism Is Dependent Solely upon the Surgeon’s Choice of Operative Procedure
  Journal of the American College of Surgeons, 1998
• Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism.
  American Journal of Roentgenology, 1997
• Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism: Consensus Development Conference Statement
  Annals of Internal Medicine, 1991
• 99Tcm sestamibi — a new agent for parathyroid imaging
  Nuclear Medicine Communications, 1989